ABT 413

Drug Profile

ABT 413

Alternative Names: ABT-413

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class Antirheumatics
  • Mechanism of Action Sphingosine 1 phosphate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Multiple-sclerosis in USA
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in USA
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top